The following is a summary of "Association of eosinophil-to-monocyte ratio with asthma exacerbations in adults: a ...

The dipeptidyl peptidase 1 (DPP-1) inhibitor cut the annualized rate of pulmonary exacerbations by around 20% compared with ...

Continuing our series, Dr Andrew Whittamore debunks some common myths about asthma – and explains some less well-known facts ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared ...

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

Drilling down into subgroups of patients, Sanofi also claimed that amlitelimab demonstrated “compelling efficacy” in patients ...

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD: Paris Wednesday, April 16, 2025, 10:00 Hrs [IST] Sanofi shared new pro ...